The realisation of targeted antitumour therapy.

摘要: Better understanding of the pathways regulating proliferation and metastasis cancer cells has led to development novel molecular-targeted therapies. The number agents approved for use in clinic is growing, with many more clinical trials. Most these compounds can be broadly classified into two main categories: monoclonal antibodies small-molecule tyrosine kinase inhibitors. pathological processes targeted include vascular endothelial growth factor-dependent tumour angiogenesis epidermal factor receptor-dependent cell survival. Unlike conventional chemotherapy, offer potential advantages a relatively high therapeutic window combination other anticancer strategies without overlapping toxicity. It hoped that drugs will become valuable tools within multimodal approach treating cancer. Recent progress antitumour therapy discussed, focus on antiangiogenesis.